Scholarlink

<p>Gastric and upper gastrointestinal (GI) oncology is at a point of transformation, with significant advances in each aspect of the disease continuum. Novel clinical tools and therapies, including randomized phase II and III trials, have provided new standards of care for patients, including preoperative chemoradiation for resectable gastric cancer and PD-L1 stratified immuno-chemotherapy in the metastatic setting. Also, many discoveries are co-evolving with newer methods, such as CAR-T therapy or reintroduced microbial undercover agents or burgeoning precision tools. However, obstacles remain, nursing the costs of CAR-T, the paradoxical survival benefit of PD-L1 P146R polymorphism, and other biological ineptitudes along with health system barriers. In this synthesis, we advocate for more closely integrated “bench-to-community” approaches to apply more effective combinations of health population prevention programs, biomarker-guided therapeutics, and omics profiling studies to accelerate and positively impact healthcare practices addressing biological or health system barriers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gastric and upper gastrointestinal oncology: integrating breakthroughs from prevention to precision therapeutics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • JunLi Chen,
  • JiLong Wang,
  • LuLu Cai,
  • Jian Li

摘要

Gastric and upper gastrointestinal (GI) oncology is at a point of transformation, with significant advances in each aspect of the disease continuum. Novel clinical tools and therapies, including randomized phase II and III trials, have provided new standards of care for patients, including preoperative chemoradiation for resectable gastric cancer and PD-L1 stratified immuno-chemotherapy in the metastatic setting. Also, many discoveries are co-evolving with newer methods, such as CAR-T therapy or reintroduced microbial undercover agents or burgeoning precision tools. However, obstacles remain, nursing the costs of CAR-T, the paradoxical survival benefit of PD-L1 P146R polymorphism, and other biological ineptitudes along with health system barriers. In this synthesis, we advocate for more closely integrated “bench-to-community” approaches to apply more effective combinations of health population prevention programs, biomarker-guided therapeutics, and omics profiling studies to accelerate and positively impact healthcare practices addressing biological or health system barriers.